← Back to Search

Anti-tumor antibiotic

Tamoxifen vs Etoposide for Recurrent Glioblastoma

Phase 2
Recruiting
Research Sponsored by AHS Cancer Control Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test within 72 hours prior to the first dose of study treatment. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes
Age from 18-65 years
Must not have
Substantial cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (> New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up throughout study completion, up to 5 years.
Awards & highlights
No Placebo-Only Group

Summary

This trial will compare two treatments for people with a certain type of brain cancer.

Who is the study for?
This trial is for adults aged 18-65 with confirmed GBM that's worsened after initial treatment. They must have a measurable tumor on MRI, stable or reduced steroid use, and be in fair to good health (ECOG 0-2). Women who can bear children need a recent negative pregnancy test and agree to effective birth control during the study.
What is being tested?
The study compares two drugs, etoposide and tamoxifen, for treating first recurrence of GBM. It's a phase II trial where patients are randomly assigned to receive one of these treatments at a single center.
What are the potential side effects?
Possible side effects from etoposide include low blood counts, nausea, hair loss, and increased risk of infection. Tamoxifen may cause hot flashes, mood swings, blood clots, and vision changes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a woman who can have children and have a recent negative pregnancy test.
Select...
I am between 18 and 65 years old.
Select...
My GBM cancer has worsened after initial treatment with temozolomide.
Select...
I can take care of myself and perform daily activities.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not had major heart or stroke issues in the last 6 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~throughout study completion, up to 5 years.
This trial's timeline: 3 weeks for screening, Varies for treatment, and throughout study completion, up to 5 years. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
3 month progression-free survival
Secondary study objectives
Adverse events
Health-related quality-of-life status
One-year progression-free survival
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: TamoxifenExperimental Treatment1 Intervention
Group II: EtoposideActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tamoxifen
2005
Completed Phase 4
~30110

Find a Location

Who is running the clinical trial?

AHS Cancer Control AlbertaLead Sponsor
182 Previous Clinical Trials
26,654 Total Patients Enrolled
7 Trials studying Glioblastoma
349 Patients Enrolled for Glioblastoma

Media Library

Etoposide (Anti-tumor antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT04765098 — Phase 2
Glioblastoma Research Study Groups: Etoposide, Tamoxifen
Glioblastoma Clinical Trial 2023: Etoposide Highlights & Side Effects. Trial Name: NCT04765098 — Phase 2
Etoposide (Anti-tumor antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04765098 — Phase 2
~20 spots leftby Aug 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top